Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN)

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy For Researchers Data Labs ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) | stella

Back to Neurofibromatosis Type 1 (NF1) trials

Recruiting

Plain-English translation of NCT07888517 on ClinicalTrials.gov ↗ · Source last updated October 2026 · How we translate trials

Trial locations(26 sites)

China

Research site, Beijing

Research site, Changchun

Research site, Changsha

Research site, Chengdu

Research site, Chongqing

Key details

Sponsor

AstraZeneca

Enrollment target

~800 participants

Started

September 2026

Primary completion

December 2030

Age range

18 Years and older

Last updated on clinicaltrials.gov in October 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

AstraZeneca Clinical Study Information Center

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov